US HB1825 | 2023-2024 | 118th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on March 28 2023 - 25% progression, died in committee
Action: 2023-04-07 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on March 28 2023 - 25% progression, died in committee
Action: 2023-04-07 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To clarify that the Federal Right to Try law applies to schedule I substances for which a phase I clinical trial has been completed and to provide access for eligible patients to such substances pursuant to the Federal Right to Try law.
Title
Right to Try Clarification Act
Sponsors
Rep. Earl Blumenauer [D-OR] | Rep. Nancy Mace [R-SC] | Rep. Madeleine Dean [D-PA] | Rep. Andy Biggs [R-AZ] |
Rep. Luis Correa [D-CA] |
History
Date | Chamber | Action |
---|---|---|
2023-04-07 | House | Referred to the Subcommittee on Health. |
2023-03-28 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2023-03-28 | House | Sponsor introductory remarks on measure. (CR E267) |
2023-03-28 | House | Introduced in House |
Subjects
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/118th-congress/house-bill/1825/all-info |
Text | https://www.congress.gov/118/bills/hr1825/BILLS-118hr1825ih.pdf |